Side-by-side comparison of AI visibility scores, market position, and capabilities
Denver healthcare REIT (NYSE: DOC) $21B combined; Healthpeak + Physicians Realty Trust merger Mar 2024, life science labs (SF/SD/Boston) + 300+ MOBs, competing with Alexandria Real Estate and Ventas.
Healthpeak Properties, Inc. is a Denver, Colorado-based healthcare real estate investment trust — publicly traded on the New York Stock Exchange (NYSE: DOC) as an S&P 500 Real Estate component — owning, operating, and developing healthcare-focused real estate including life science laboratory buildings (biopharmaceutical R&D facilities in South San Francisco, San Diego, Boston), medical office buildings (outpatient care facilities adjacent to major hospital campuses), and continuing care retirement communities through approximately 400 employees. In March 2024, Healthpeak Properties (then trading as HCP/PEAK) completed its $21 billion merger of equals with Physicians Realty Trust (DOC — medical office REIT with 300+ medical outpatient buildings in 30+ states) — adopting Physicians Realty Trust's ticker symbol "DOC" and creating a $21 billion combined healthcare REIT with 60+ million square feet of life science labs, 18+ million square feet of medical office, and the most diversified healthcare real estate portfolio among public healthcare REITs. CEO Scott Brinker leads the combined company's strategy of capitalizing on the structural demand drivers for healthcare real estate: life science lab demand driven by NIH funding, private biopharma venture investment, and drug approval tailwinds — and medical office demand driven by the shift of healthcare delivery from hospital inpatient settings to outpatient ambulatory care facilities that require real estate closer to patient populations. Healthpeak's life science portfolio in the three dominant biotech clusters (San Francisco Bay Area, San Diego's Torrey Pines/UTC corridor, Boston's Kendall Square/Route 128 corridor) positions it in the markets where biopharma and biotech tenants require Class A laboratory space for drug discovery and development.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.